|
|
Post by goyocafe on Apr 3, 2018 12:50:23 GMT -5
All this talk of making Afrezza the standard of care makes me me wonder exactly what that means. In terms of the recommended treatments for the various stages/progression of the disease, are they shooting to just make Afrezza the first insulin of choice, perhaps even over basal (for T2s)? Or are they trying to create a whole new treatment paradigm where insulin (Afrezza) plays a role in the earliest treatment regimines?
|
|
|
|
Post by sweedee79 on Apr 3, 2018 14:42:40 GMT -5
In my mind it means more stringent treatment of hyper and hypoglycemia ... tighter control of the disease.. better outcomes for people with diabetes.. Afrezza offers that. In combination with cgms etc..
|
|
|
|
Post by goyocafe on Apr 3, 2018 15:11:43 GMT -5
In my mind it means more stringent treatment of hyper and hypoglycemia ... tighter control of the disease.. better outcomes for people with diabetes.. Afrezza offers that. In combination with cgms etc.. So the "standard of care" you are referring to would suggest that when insulin is required, recommend Afrezza? That was the first choice in my post. The reason I posed the questions is that the course to both ends will be quite different, with the latter (going for early use of Afrezza in the treatment of the disease) being a much taller order (and longer to reach that goal). But as someone posted, this isn't going to be like switching on a light. This will be a glow that grows brighter and brighter. I'd be happy just to see doctors more open to prescribing just to get scripts up. |
|
|
|
Post by liane on Apr 3, 2018 15:25:14 GMT -5
This thread has strayed far and wide from the original topic (which I don't want to give any more attention). So I'm locking it.
|
|
